HRTX
Price
$1.05
Change
-$0.00 (-0.00%)
Updated
Nov 21, 04:59 PM (EDT)
Capitalization
193.45M
103 days until earnings call
Intraday BUY SELL Signals
MDGL
Price
$547.43
Change
+$5.31 (+0.98%)
Updated
Nov 21, 04:59 PM (EDT)
Capitalization
12.44B
103 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HRTX vs MDGL

Header iconHRTX vs MDGL Comparison
Open Charts HRTX vs MDGLBanner chart's image
Heron Therapeutics
Price$1.05
Change-$0.00 (-0.00%)
Volume$25.42K
Capitalization193.45M
Madrigal Pharmaceuticals
Price$547.43
Change+$5.31 (+0.98%)
Volume$7.27K
Capitalization12.44B
HRTX vs MDGL Comparison Chart in %
HRTX
Daily Signal:
Gain/Loss:
MDGL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
HRTX vs. MDGL commentary
Nov 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HRTX is a Hold and MDGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 22, 2025
Stock price -- (HRTX: $1.05 vs. MDGL: $542.12)
Brand notoriety: HRTX and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HRTX: 152% vs. MDGL: 77%
Market capitalization -- HRTX: $193.45M vs. MDGL: $12.31B
HRTX [@Biotechnology] is valued at $193.45M. MDGL’s [@Biotechnology] market capitalization is $12.31B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.15B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HRTX’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • HRTX’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than HRTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HRTX’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 5 bullish TA indicator(s).

  • HRTX’s TA Score: 4 bullish, 6 bearish.
  • MDGL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than HRTX.

Price Growth

HRTX (@Biotechnology) experienced а -4.95% price change this week, while MDGL (@Biotechnology) price change was +5.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.93%. For the same industry, the average monthly price growth was -3.16%, and the average quarterly price growth was +63.47%.

Reported Earning Dates

HRTX is expected to report earnings on Mar 04, 2026.

MDGL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-0.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($12.4B) has a higher market cap than HRTX($193M). MDGL YTD gains are higher at: 77.580 vs. HRTX (-31.046). HRTX has higher annual earnings (EBITDA): 7.54M vs. MDGL (-266.74M). MDGL has more cash in the bank: 797M vs. HRTX (40.6M). MDGL has less debt than HRTX: MDGL (124M) vs HRTX (177M). MDGL has higher revenues than HRTX: MDGL (516M) vs HRTX (150M).
HRTXMDGLHRTX / MDGL
Capitalization193M12.4B2%
EBITDA7.54M-266.74M-3%
Gain YTD-31.04677.580-40%
P/E RatioN/AN/A-
Revenue150M516M29%
Total Cash40.6M797M5%
Total Debt177M124M143%
FUNDAMENTALS RATINGS
HRTX vs MDGL: Fundamental Ratings
HRTX
MDGL
OUTLOOK RATING
1..100
7115
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
10019
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
8436
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (63) in the Pharmaceuticals Other industry is in the same range as HRTX (69) in the Biotechnology industry. This means that MDGL’s stock grew similarly to HRTX’s over the last 12 months.

MDGL's Profit vs Risk Rating (19) in the Pharmaceuticals Other industry is significantly better than the same rating for HRTX (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than HRTX’s over the last 12 months.

MDGL's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as HRTX (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to HRTX’s over the last 12 months.

MDGL's Price Growth Rating (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for HRTX (84) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than HRTX’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as HRTX (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to HRTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HRTXMDGL
RSI
ODDS (%)
Bullish Trend 16 days ago
89%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
HRTX
Daily Signal:
Gain/Loss:
MDGL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NXNIF0.160.02
+14.22%
NORTHX NICKEL CORP.
FPRGF0.250.02
+7.55%
Falco Resources Ltd.
SVNDF14.02N/A
N/A
Seven & I Holdings Co., Ltd.
SGLMF0.44N/A
N/A
Starhill Global Real Estate Investment Trust
KOBNF24.10N/A
N/A
Kobe Bussan Co., Ltd.

HRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, HRTX has been loosely correlated with GSGTF. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HRTX jumps, then GSGTF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRTX
1D Price
Change %
HRTX100%
N/A
GSGTF - HRTX
45%
Loosely correlated
N/A
AMRN - HRTX
44%
Loosely correlated
-0.30%
CYCN - HRTX
40%
Loosely correlated
+3.52%
AXON - HRTX
38%
Loosely correlated
+0.46%
LGVN - HRTX
37%
Loosely correlated
-0.51%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+1.08%
ALXO - MDGL
56%
Loosely correlated
+5.15%
IPHA - MDGL
44%
Loosely correlated
+1.10%
RNAC - MDGL
43%
Loosely correlated
+1.26%
GHRS - MDGL
43%
Loosely correlated
-0.32%
LCTX - MDGL
43%
Loosely correlated
+4.19%
More